胆固醇酯转运蛋白基因多态性与他汀类药的调脂效应
摘要
提要:胆固醇酯转运蛋白作为参与细胞胆固醇代谢过程的一个关键成员,其基因的某些单核苷酸多态如TaqIB,I405V,-629C/A,-631C/A,-971G/A等能影响他汀类药对心血管疾病患者血清胆固醇水平的调节作用。表明胆固醇酯转运蛋白基因单核苷酸多态性可能影响他汀类药的调脂效果及冠心病的疗效。
出处
《岭南心血管病杂志》
2007年第5期379-380,共2页
South China Journal of Cardiovascular Diseases
基金
广东省自然科学基金项目(项目编号KZ0409)
参考文献13
-
1[1]LUSIS A J.Atherosclerosis[J].Nature,2000,407 (6801):233-241.
-
2[2]FIEGENBAUM M,DASILVEIRA F R,VANDER-SAND C R,et al.The role of common variants of ABCB1,CYP3A4,and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment[J].Clin Pharmacol Ther,2005,78(5):551-558.
-
3[3]CARLQUIST J F,MUHLESTEIN J B,HORNE B D,et al.The cholesteryl ester transfer protein TaqIB gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease[J].Am Heart J,2003,146 (6):1007-1014.
-
4[4]KUIVENHOVEN J A,JUKEMA J W,ZWINDERMAN A H,et al.The role of a common variant of the cholesteryl ester transfer protein gene in the progression of cornary atherosclerosis.The Regression Growth Evaluation Statin Study Group[J].N Engl J Med,1998,338 (2):86-93.
-
5[5]Kotake H,Sekikawa A,Tokita Y,et al.Effect of HMG-CoA Reductase Inhibitor on plasma cholesteryl ester transfer protein activity in primary hypercholesterolemia:comparison among CETP/TAQIB genotype subgroups[J].J Atheroscier Thromb,2002,9(5):207-212.
-
6[6]VANVENROOIJ F V,STOLK R P,BANGA J D,et al.Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes[J].Diabetes Care,2003,26 (4):1216-1223.
-
7[7]BOEKHOLDT S M,SACKS F M,JUKEMA J W,et al.Cholesteryl ester transfer protein TaqIB variant,high-density lipoprotein cholesteterol levels,cardiovascular risk,and efficacy of pravastatin treafment:individual patient metaanalysis of 13,677 subjects[J].Circulation,2005,111 (3):278-287.
-
8[8]DE GROOTH G J,ZERBA K E,HUANG S P,et al.The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study:no interaction with the response to parvastatin therapy and no effects on cardiovascular outcome:a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy[J].J Am Coil Cardiol,2004,43 (5):854-857.
-
9[9]FREEMAN D J,SAMANI N J,WILSON V,et al.A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovacular events in non-smokers in the west of Scotland coronary prevention study[J].Eur Heart J,2003,24(20):1833-1842.
-
10[10]BLANKENBERG S,RUPPRECHT H J,BICKEL C,et al.Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease[J].J Am Coll Cardiol,2003,41 (11):1983-1989.
二级参考文献6
-
1Manzoni M, Rollini M.Biosynthesis and biotechnological production of statins by filamentous fungiand application of these cholesterol-lowering drugs.Appl Microbiol Biotechnol 2002;58(5):555-64
-
2Vaughan CJ, Delanty N.Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999;30(9):1969-73
-
3Maitland-van der Zee AH, Klungel OH, Stricker BH,et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors.Atherosclerosis 2002;163(2):213-22
-
4Yamashita S, Hirano K, Sakai N,et al. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein.Biochim Biophys Acta 2000; 1529( 1-3):257 -75
-
5Schafer AJ, Hawkins JR.DNA variation and the future of human genetics.Nat Biotechnol 1998;16(1):33-9
-
6Kotake H, Sekikawa A, Tokita Y,et al. Effect of HMG-CoA reductase inhibitor on plasma cholesteryl ester transfer protein activity in primary hypercholesterolemia: comparison among CETP/TaqIB genotype subgroups.J Atheroscler Thromb 2002;9(5):207-12
共引文献6
-
1寿峰勤,金轶,杨小英.胆固醇酯转运蛋白I405V多态位点与辛伐他汀对血脂异常患者调脂疗效的关联性[J].中国生化药物杂志,2014,34(3):48-51. 被引量:3
-
2郭志斌,郑克勤.胆固醇酯转运蛋白基因多态性与他汀类药物的调脂效应[J].生命的化学,2009,29(1):90-93.
-
3付秀敏,叶丽卡.辛伐他汀的药物基因组学研究进展[J].今日药学,2009,19(6):13-16. 被引量:2
-
4高静,刘寅,王林.胆固醇酯转运蛋白基因多态性与他汀类药物调脂疗效的研究进展[J].中华老年心脑血管病杂志,2012,14(1):100-102. 被引量:4
-
5曹力,李志勇,涂云明.性别对辛伐他汀治疗2型糖尿病伴血脂异常的疗效影响[J].实用中西医结合临床,2013,13(6):13-14. 被引量:1
-
6李志勇,涂云明.辛伐他汀治疗合并高血压血脂异常的2型糖尿病患者的疗效观察[J].临床合理用药杂志,2014,7(29):51-52. 被引量:1
-
1潘其兴,王敏,李晓东,马珂,陈淑琴.普罗布考调脂效应的临床观察[J].山东医科大学学报,1999,37(1):74-76. 被引量:1
-
2杨轶青,蒋慧君,韦红金,夏金荣.辛伐他汀治疗早期糖尿病肾病的疗效评价[J].临床荟萃,2011,26(19):1674-1676. 被引量:12
-
3沈云峰,赖晓阳,张美英,刘泽,林余戎.氟伐他汀对2型糖尿病患者尿微量白蛋白的影响[J].中国综合临床,2008,24(6):526-528. 被引量:1
-
4施仲伟.急性冠脉综合征早期他汀类药物治疗的临床试验[J].中国医药导刊,2002,4(5):383-385. 被引量:8
-
5李克华.冠心病发病及危险因素的相关研究[J].吉林医学,2005,26(12):1368-1369.
-
6邱媛,聂丹,于婕.再谈他汀的非调脂效应[J].中华临床医师杂志(电子版),2015,9(22):90-93.
-
7夏志琦,闫少迪,卢奕.CYP3A4基因多态性对冠心病患者阿托伐他汀调脂效应及预后的影响[J].临床医学工程,2015,22(1):71-72. 被引量:1
-
8白家和.脂必泰与阿托伐他汀心血管调脂疗效的对比研究[J].中国现代药物应用,2010,4(24):24-25. 被引量:12
-
9刘晋秦,祖凌云,赵春玉,薛琳,张岩,李建平,高炜.胆固醇酯转运蛋白基因I405V多态性与辛伐他汀的调脂效应[J].中国临床康复,2005,9(31):102-104. 被引量:7
-
10万槐斌,成锦,周婉明,唐良秋,张社兵.阿托伐他汀联合小檗碱对稳定型心绞痛患者血脂水平的影响[J].中国循证心血管医学杂志,2013,5(1):19-20. 被引量:9